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Summary Five patients with a pleural malignancy (four malignant mesotheliomas and one localized low grade carcinoid) were treated with
maximal surgical resection of the tumour followed by intraoperative adjuvant photodynamic therapy (PDT). The additional photodynamic
treatment was performed with light of 652 nm from a high power diode laser, and meta-tetrahydroxy phenylchlorin as the photosensitizer. The
light delivery to the thoracic cavity was monitored by in situ isotropic light detectors. The position of the light delivery fibre was adjusted to
achieve optimal light distribution, taking account of reflected and scattered light in this hollow cavity. There was no 30-day post-operative
mortality and only one patient suffered from a major complication (diaphragmatic rupture and haematopericardium). The operation time was
increased by a maximum of 1 h to illuminate the total hemithoracic surface with 10 J cm-2 (incident and scattered light). The effect of the
adjuvant PDT was monitored by examination of biopsies taken 24 h aftersurgery underthoracoscopic guidance. Significantdamage, including
necrosis, was observed in the marker lesions with remaining malignancy compared with normal tissue samples, which showed only an
infiltration with PMN cells and oedema of the striated muscles cells. Of the five patients treated, four are alive with no signs of recurrent tumour
with a follow-up of 9-11 months. One patient was diagnosed as having a tumour dissemination in the skin around the thoracoscopy scar and
died of abdominal tumour spread. Light delivery to large surfaces for adjuvant PDT is feasible in a relatively short period of time (< 1 h). In situ
dosimetry ensures optimal light distribution and allows total doses (incident plus scattered light) to be monitored at different positions within the
cavity. This combination of light delivery and dosimetry is well suited for adjuvant treatment with PDT in malignant pleural tumours.
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Pleural tumours, especially malignant mesothelioma (MM), are
considered to be incurable as at diagnosis the disease is usually
advanced and spreads diffusely in the pleural space. Radical resec-
tions can seldom be performed. Macroscopically, the resection may
appear complete but microscopically tumour cells are often evident
(Butchart and Gibbs, 1990). Forthose cases that are considered to be
surgical candidates, adjuvant treatments have mostly been given in
the form ofradiation therapy (Hilaris etal, 1984; DaValle et al, 1986)
and chemotherapy (Sugarbaker et al, 1991; Rusch et al, 1994).
Despite somepositive results from these studies, overall survival was
not significantly improved, whereas side-effects were increased.
Irradiation of a large field, including organs like the spinal cord,
heart, oesophagus and liver, makes itdifficult forthe radiation oncol-
ogist to give an adequate radiation dose without exceeding normal
tissue tolerance. Chemotherapy has sofarshowntobeofonly limited
use in the primary treatment ofmalignant mesothelioma (Chahinian
et al, 1982, 1993; S0rensen et al 1985; Krarup-Hansen and Hansen,
1991; Ruffle, 1993), but the most active compounds (e.g. doxoru-
bicin) might be ofuse for the treatment ofminimal residual tumour.
Post-operative chemotherapy is, however, associated with liver and
kidney toxicity and it may be difficult to achieve adequate drug
concentration in the areas with reduced perfusion afterresection.
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Photodynamic therapy (PDT) has been used by several investiga-
tors as an adjuvant treatment for MM but in most cases the condi-
tions were not optimal (Lofgren 1991; Ris et al, 1991, 1996; Pass et
al, 1994; Takita et al, 1994). Lack ofhigh powerlasers and effective
photosensitizers with a high singlet oxygen yield, plus a lack of
knowledge of the dosimetric aspects of light distribution and scat-
tering in a hollow cavity, limited the general usefulness ofthis form
of treatment. Haematoporphyrin derivatives were used in most
studies but the excitation wavelength (630 nm) has only a limited
penetration in tissue and the singlet oxygen yield is low for these
sensitizers. Ris and colleagues (1996) were the first to publish a
study using a second generation photosensitizer, m-THPC (meta-
tetrahydroxyphenylchlorin), for the treatment ofMM. m-THPC has
a longer excitation wavelength (652 nm), resulting in somewhat
better tissue penetration, and a much higher singlet oxygen yield
than haematoporphyrin derivative sensitizers. One potential
problem in this study was that the light was administered sequen-
tially to fields in the thoracic cavity by using a cut-off fibre and
microlens. This technique inevitably resulted in overlapping illumi-
nation fields. In addition, no account was taken of the contribution
of scattered light to the total light dose. The doses quoted, based on
incident light alone, will therefore be an underestimate of the light
dose to tissues in the illuminated cavity.
In this feasibility study we have tested a new method of light
application using a high-power diode laser and real time, in situ
measurement of light delivery to the tissue in the thoracic cavity
after macroscopically complete resection ofthe tumour.
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MATERIALS AND METHODS
Patient selection
In the period from January to June 1996, patients with a histolog-
ical diagnosis of malignant mesothelioma were asked to partici-
pate in this study. In addition to extensive surgical and pulmonary
work up, they had to fulfil the following criteria: performance
status < 1 (ECOG), age <70 years, weight loss <10 % in the
preceding 3 months, adequate cardiac function to accept a pneu-
monectomy and a calculated pulmonary rest capacity of> 1 1 s-'
expiration after resection. The surgical work up consisted of a
computerized tomography (CT) scan to exclude possible ingrowth
in major organs such as the vertebrae, the heart and lymph nodes.
All patients had a thoracoscopic examination and mediastinoscopy
for optimal diagnosis and staging. The new staging criteria
according to the Intermational Mesothelioma Interest Group
(IMIG, 1995) were used. Patients with positive lymph nodes at
mediastinoscopy or distant metastasis were excluded from the
study. Details of patient and tumour characteristics are given in
Table 1.
Surgical procedure
Patients were intubated selectively by a double-lumen tube and
placed in a lateral decubitus position. The previous entrance port
of thoracoscopy or thoracotomy was excised and an extrapleural
resection was initiated. To reduce the chance of 'sunbum', the
theatre lights were out of focus and the normal skin was
completely covered by sheets. The pleural tumour was resected
extrapleurally on the side confined to the ribs and mediastinum;
resection of tumour from the pericardium and the diaphragm was
more difficult. To facilitate the pleural resection and to limit blood
loss, a cavitron ultrasound surgical aspirator (CUSA) was used. In
patients with extensive involvement of the visceral pleura, a pneu-
monectomy was performed. The surgical aim was to achieve
macroscopic tumour resection, but in areas that were unsuitable
for radical resection tumour reduction to < 5 mm thickness was
performed. To prevent local tumour spread beyond the thoracic
cavity, the normal boundaries (such as pericardium and
diaphragm) of the thoracic cavity were left intact. An ipsilateral
lymph node dissection was part of the pleural pneumonectomy
procedure. The bronchial stump was closed using staples (TA 55,
Autosuture). To obtain histological specimens after the combined
treatment, a thoracoport (Thoracoport, Autosuture) was inserted in
the upper part of the anterior chest wall and covered with sterile
adhesive tape. A small marker lesion, easily accessible by thora-
coscopy, was left behind and indicated by a suture. Patients were
detubated immediately post-operatively and monitored in the
intensive care unit (ICU). Oxygen saturation was measured for a
few minutes every hour using a finger clamp (red light). Fluid
replacement was administered according to vital signs, blood pres-
sure and urinary output balanced with the anticipated perspiration.
Photodynamic procedure
Patients were injected with 0.1 mg kg-' mTHPC (Scotia
Pharmaceuticals, Guildford, UK) 4 days before the operation.
Twenty milligrams of the drug was dissolved in 5 ml of solvent,
containing ethanol, polyethylene glycol and water and shaken for
5 min. The drug was given intravenously as a slow push injection
(4 mg ml-'). After administration, patients were nursed in subdued
light for a minimum of 2 weeks.
The thoracic cavity was integrally illuminated with a spherical
diffusing fibre (bulb diameter 3 mm, Rare Earth Medical, West
Yarmouth MA, USA). Ifnecessary, a micro-lens fibre (PDT, Santa
Barbara CA, USA) was used for additional local illumination. The
fibre was coupled to a diode laser (Applied Optronics, 6 W),
which provided 6W oflight at 652 nm. During a pilot experiment,
in which we measured the fluence rate distribution in the thoracic
cavity of a (non-sensitized) patient after pneumonectomy, we
observed that the region near the diaphragm posed a problem for
illumination. Because of the absence of the lung mass, the
diaphragm folds into the thoracic cavity and forms a region (sinus)
where the light is shadowed. A transparent sterile plastic bag
(Steri-Drape, 3M) was therefore placed in the thoracic cavity and
filled with saline (at body temperature) to stretch the diaphragm.
This resulted in a better distribution of the light. Before placing
and fitting the transparent sterile bag, optimal haemostasis was
obtained and the thoracic cavity was cleaned thoroughly to prevent
light absorption by blood. The light source was introduced via a
sterile tube (stomach catheter 18G) in the centre of the filled bag.
The surgical wound was approximated during the illumination to
maximize back scattering of light due to reflections in the cavity.
This procedure was performed to obtain a uniform light distribu-
tion. Before and after illumination, the presence of blood pockets
was easily verified by visual inspection of the saline in the bag.
The distribution and total dose of the light delivered was moni-
tored with isotropic light detectors (probes) with an accuracy of
± 15% (Van Staveren et al, 1995), manufactured in the Clinical
Physics Department of the Daniel den Hoed Cancer Centre. The
probes (diameter 1 mm) were connected to photodiodes (Photop
UDT-455, Graseby Electronics, Orlando FL, USA), the output of
which was A/D converted and displayed and stored on a PC. This
system allowed us to do real-time fluence rate and integrated
fluence measurements. The isotropic probes measure the total
light fluence delivered to the tissue, including both direct incident
and scattered light from the tissue bulk. The latter is not measured
when flat photodiodes are used, as in some previous studies of
PDT in malignant mesothelioma (Pass et al, 1994).
The probes were calibrated in air in an integrating sphere with a
well defined diffuse light field (Van Staveren et al, 1995). The
integrating sphere and the photodiodes are incorporated in one
device that can be connected to the printer port of any regular PC.
The probes were then placed in a sterile polyethylene lockable
extension tube (i.d. 1-2 mm, Vygon, Ecouen, France) and filled
with saline to match the refractive index of the surrounding
medium (saline and tissue), which resulted in correct calibration of
the isotropic probes. For further details on these calibrations see
Marijnissen and Star (1996). Four probes were used to monitor the
treatment. The probes (in the tubes) were sutured at strategic spots
in the thoracic cavity before the sterile bag with saline was placed
in position. One probe was always situated in the sinus, and one in
the top of the thoracic cavity. The third and the fourth probes were
positioned to cover representative areas of the cavity, including
critical structures such as the oesophagus, the pericardium or the
lung surface ifonly a pleurectomy was performed.
At the start ofthe treatment, the spherical diffuser was placed in
the centre ofthe cavity and the position ofthe diffuser was manu-
ally adjusted until the fluence rate readings on all detector probes
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Figure 1 Chest radiograph (posteroanterior view) of this patient before
operation. The arrows indicate the contours of the mesothelioma on the right
side
were approximately equal. Ifthe detectors showed an imbalance in
fluence rate during the treatment, the diffuser was manually
repositioned to regain the desired distribution. If a region (e.g. the
sinuses) received insufficient light, this region was given top up
illumination using a micro-lens fibre after removal of the saline
filled bag. The four probes were recalibrated (software-wise) for
the absence of the saline (which causes a refractive index
mismatch), and left in place to measure the scattered light at other
than the directly illuminated regions. The illumination was
continued until the required total dose of 10 J cm-2 was reached,
averaged over all measured sites. Sometimes an imbalance
between the total light dose on the four spots was allowed, for
instance when the probe was on a spot with a visible tumour mass.
Twenty-four hours after treatment a thoracoscopy was
performed (four patients) through the thoracoport with a 00 rigid
optic held in a forceps device (Wolf, Germany). Biopsies were
taken from apparently normal tissue andfromthe marked indicator
lesions. The tissue was collected in formaldehyde and processed
for histology. The thoracoport was replaced by a transparent tube
and additional illumination (20 J cm-' at 400 mW cm-' using a 2-
cm cylindrical diffuser) was given to the tract in order to kill any
remaining tumour cells.
RESULTS
Five patients were suitable for the combined surgical/PDT treat-
ment. The mediastinoscopy was normal in these patients, there
were no contraindications for apleuropneumonectomy and written
informed consent was obtained. Four of the patients had diffuse
mesothelioma (confirmed by an expert panel) for which a pleuro-
pneumonectomy was indicated. The chest radiograph of the first
patient is shown in Figure 1. One patient with a localized lesion
was treated with excision of the pleural tumour and was illumi-
nated with the lung in situ. This patient was found to have a carci-
noid tumour instead of a malignant mesothelioma when the
excised tumour was analysed (Table 1). A sixth patient referred for
the adjuvant PDT therapy proved to be irresectable at operation.
The operation was therefore terminated and no additional PDT
was given.
The total PDT treatment time was (maximally) 1 h, including
placement of the probes and the bag. The integrated cumulative
dose (J cm-2) is shown as a function of time for all patients in
Figure 2A-E and the delivered dose to all sites of measurement is
given in Table 2.
In patient 1 the fluence rates on all but one probe were balanced
(Figure 2A). The probe in the sinus showed a low fluence rate, indi-
cating thatthe diaphragm was notproperly stretched. The total light
dose tothe sinus was less than 1 Jcm-2. Two additional illuminations
using a micro-lens were therefore given. The bag was removed and
the diaphragm stretched manually, leaving the other probes in situ.
The probe nearthe oesophagus registered an additional light dose of
2.5 J cm-2 as a result ofthe scattered light from the micro-lens illu-
minations, the otherprobes showed an additional dose of 1.5 J cm-2.
The probe located in the sinus was used to measure the additional
dose given by the micro-lens. The total dose on the diaphragm,
outside the areas that were additionally illuminated, is estimated to
be about 1 J cm-2 higher than the initial dose of 8.6 J cm-2. The
average dose for the entire cavity was 10.1 J cm-2.
In patient 2 the (deflated) lung was still present in the thoracic
cavity. The dose on the lung surface was monitored to avoid exces-
sive normal tissue damage (Figure 2B). The fluence rate on the
probes was balanced, except for the probe on the tumour located
on the lateral thoracic wall. The tumour surface was additionally
Table 1 Patient and tumour characteristics
Patient no. Age (years) Sex Diagnosis TNM after resection Side Comments
1 37 M Epithelioid T3N1MO Right Extensive tumour mass on diaphragm and mediastinum, pretreatment
with one course of mitomycin C, vinblastine and cisplatin
2 40 M Carcinoid TxNOMO Left Localized tumour in the parietal pleura (9 cm diameter) that was first
diagnosed as a MM at thoracoscopy
3 59 M Epithelioid T2N1MO Right Large tumour mass on parietal pleura, diaphragmatic sinuses and in the
diaphragm
4 41 F Epithelioid Ti bNOMO Left Tumour located especially at the diaphragmatic sinuses
5 54 M Epithelioid T3NOMO Right Tumour diffusely located in the thorax with location in the top that was
difficult to remove surgically.
Tib, tumour extending on both visceral and parietal pleura; T2, tumour with in growth of the lung or diaphragm; T3, tumour encompassing the pericardium; NO,
no lymph nodes; Ni, positive lymph nodes within the visceral pleura; MO, no distant metastases.
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Figure 3 Fluence rate (mW cm-2) recorded in time (min) during the illumination of the thoracic cavity of patient 4. Small changes in fluence rate occur during
illumination because of respiration and the manual repositioning of the light probe
Table 2 Total cumulative light doses delivered to various sites in the thoracic cavity.
Light dose (J cm-2)
Probe position Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Top of thoracic cavity 9.8 9.9 8.5 8.5 8.5
Lung surface - 10.5
Retrosternal 10.2 - -
Oesophagus/mediastinum 11.7 - 7.8
Tumour - 12.8
Pericardium - - 8.5 10.4
Thorax surgical entrance - - 10.5 9.1 10.2
Diaphragmatic sinus < 1.0 9.0 14.4 9.4 8.5
Extra sinus illumination, anterior and posterior 8.6 -
Average 10.1 10.0 10.3 8.9 9.4
illuminated with a micro-lens. In this situation the scattered light
contributed little extra dose to the other sites of measurement. The
diaphragm was well stretched and the light dose in the sinus was
sufficient. The tumour received 12.8 J cm-2, the average for the
cavity was 10.6 J cm-2.
In patient 3 well-balanced fluence rates were established on all
probes (Figure 2C), with, intentionally, ahigher fluence rate on the
sinus, which received 14.4 J cm-2 to the remainder oftumour mass
on the diaphragm. The average dose delivered was 10.3 J cm-2.
In patients 4 and 5 the fluence rates on all probes were well
balanced (Figure 2D and E). Average doses for the cavity were 8.9
and 9.4 J cm-2 respectively. Changes in fluence rate during the
illumination period for patient 4 is illustrated in Figure, 3. Apart
from the fluctuations caused by the manual repositioning of the
spherical diffuser, the fluence rate on all probes was kept stable at
3-4 mW cm-2.
Post treatment complications and follow-up
There was no 30 day mortality and the duration ofthe hospital stay
was less than 3 weeks for patients 1, 2, 3 and 5 (Table 3).
In patient 1, skin photosensitivity occurred in the intensive care
unit because of monitoring with a pulse-oximeter on the index
finger. A small grade 2 sunburn resulted from the measurement
(which lasted 4 h). (Other patients were monitored intermittently
for several seconds on different fingers.) Eleven months after the
operation patient 1 was in good clinical condition and had resumed
working full time. A CT scan showed no evidence oftumour recur-
rence in the thoracic cavity. Patient 2 had recovered fully from the
operation and resumed working part-time at 10 months after opera-
tion. Physical and radiological examination did not reveal any
recurrences and the lung function parameters (spirometry and
diffusion) were unchanged. The third patient suffered from consti-
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Table 3 Post-surgical complications and follow-up
Patient no. Hospital stay (days) Complication (post-operative) Follow-up (months) Current tumour status and long-term side-effects
1 18 Grade 2 sunburn on index finger 11, alive No evidence of tumour recurrence
2 16 No complications 10, alive No evidence of tumour recurrence, fatigue since operation
3 18 Constipation due to opiates 7, dead Diffuse vascular metastasis originating from the
thoracoport leading to abdominal metastasis and death
4 41 Rupture of diaphragm requiring 10, alive No evidence of tumour recurrence, limited exercise
rethoracotomy, increased effusion tolerability, fatigue
in operated cavity treated with
multiple thoracenteses
5 20 Haematopericardium requiring 9, alive Lower back pain with normal MRI, no evidence of tumour
drainage grade 2-3 skin burn on recurrence, increased susceptibility for infections
a 5 cm area in the surgical scar
Table 4 Tumour and normal tissue response to PDT after 24 h
Patient Tumour sample Normal tissue
1 Partly necrotic, partly viable tumour cells, inflammatory cells and oedema Fat tissue, muscle cells, partly necrotic, oedema
2 No data No data
3 No tumour cells identifiable, inflammatory cells Inflammatory cells and muscle cells
4 No tumour identifiable inflammatory cells, oedema Inflammatory cells and oedema in striated muscle cells
4 at 48 h No tumour cells identifiable No necrosis of diaphragm biopsies or of chest wall biopsies
5 Necrosis of tumour cells, inflammation Fat tissue and muscle cells with some necrosis
pation related to the post-operative pain medication. Reduction of
the opiates and oral and rectal laxatives resolved this complication.
Sixteen weeks post-operatively, diffuse tumour spread was diag-
nosed in the superficial skin vessels originating from the thoraco-
scopic scar. He died of local and abdominal tumour spread at 7
months after treatment. No post mortem was performed.
In patient 4, the diaphragm was elevated one day after surgery
and thoracoscopic examination was difficult. On day 2 signs of a
diaphragmatic rupture had become apparent and a rethoracotomy
had to be performed to replace the stomach in the abdominal
cavity and to close the diaphragmatic rupture. The margins of the
rupture were biopsied and a Marlex covering was used to
strengthen the diaphragm. Increased fluid production in the
thoracic cavity resulted in shifting ofthe mediastinum to the right,
thus hampering respiration. Repeated punctures (thoracentheses)
were necessary to remove the superfluous pleural fluid. Ten days
after treatment the patient had increased dysponea and a pulsus
paradoxus was noted. On radiological examination (chest radio-
graph and ultrasound) a pericardial effusion was noted and
500 cm3 of haemorrhagic fluid was removed. Cytological exami-
nation revealed no tumour cells and the post-operatively initiated
anticoagulant therapy was withdrawn. Further recovery was
uneventful and on day 40 after admission she was discharged. Ten
months after treatment she was well with no signs oftumourrecur-
rences on CT scan examination. Patient 5 experienced post-opera-
tive pain that could be controlled with analgetics. Nine months
after treatment he was still tired but had no other complaints. The
radiological examination did not show any signs ofrecurrences.
None of the patients experienced any generalized sunburn
effects after discharge.
Histological examination
In the 4 patients who underwent pleuropneumonectomy, athoraco-
scopy was performed one day after PDT and tissue was taken from
A
B
Figure 4 (A) Pleural mesothelioma, epithelial type (H&E, 200x, pleuro-
pneumonectomy specimen) of patient 1. (B) Necrotic mesothelioma, 24 h
after combined treatment (H&E, 200x, biopsy of target lesion) of patient 1
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apparent normal and indicator lesions. In Table 4 details of the
histological specimens are given. In all specimens obtained, an
infiltration with polymorphonuclear cells and oedema was
observed. This was more marked in the tumour tissue than in the
samples obtained from the chest wall where the tumour had been
resected completely. Figure 4A shows an example of vital
mesothelioma in the resection specimen ofpatient number 1. In the
biopsies of the target lesion (Figure 4B), sampled 24 h after the
combined treatment, necrotic residual mesothelioma with an
increased number of polymorphonuclear cells was found. The
patient who was reoperated for the diaphragmatic rupture also had
tissue sampling 48 h after the PDT. Biopsies taken from the
diaphragm at the site ofrupture showed a thin muscle layer but no
evidence of(PDT induced) necrosis was found.
DISCUSSION
From the time ofdiagnosis of MM, the mean survival is generally
9-14 months despite aggressive treatment. It is well recognized
that surgery alone is insufficient for the majority of malignant
pleural mesothelioma cases and (adequate) adjuvant therapies are
limited by their toxicity and damage to normal tissue or the
inability to cover all sites of the resection areas. Various
chemotherapeutic regimens containing mitomycin-C and doxoru-
bicin have been investigated but their effectiveness has not been
demonstrated clearly. Although some long term survivors have
been reported, the overall effect has been disappointing (Krarup-
Hansen and Hansen, 1991). The addition of radiotherapy to the
operated hemithorax has also failed to demonstrate an increase in
survival (Hilaris et al, 1984; DaValle et al, 1986). One ofthe major
problems is the planning of the radiation field to administer a
tumoricidal dose without excessive normal tissue toxicity.
The primary objective of this study was to develop a suitable
illumination and dosimetry procedure for intrathoracic PDT.
Photodynamic therapy offers some advantages as a local adjuvant
treatment as it has a restricted normal tissue toxicity that is related
to the depth ofpenetration of the light used and the concentration
ofphotosensitizer. For optimal efficacy, the photosensitizer should
preferentially concentrate in tumour tissue, and/or its vasculature,
and its singlet oxygen production should be high on illumination.
A second important aspect is that optimal light delivery and
dosimetry, especially when larger areas are treated.
Promising results on the use ofPDT in MM have been reported
in the literature. In the largest study (Pass et al, 1994) 42 patients
were treated with haematoporphyrin derivative and illumination in
a phase I study, but no increased survival (mean 12.4 months) was
observed. The illumination, 2 days after sensitization, was
performed with two argon dye lasers. The fluence rate for each
laser at 630 nm was 5 W maximally and the average additional
time to perform the PDT was 89 min (including placement of
fibres). The actual laser time was 68 min to achieve a total light
dose of 25 J cm-2. As light dosimetry was performed with flat
photodiodes, which do not measure all scattered light, the total
light delivery to the tissue was underestimated. Ris et al (1996)
performed a pilot study in eight patients using 0.3 mg kg-' m-
THPC and 10 J cm-2 after an interval of 48 h. Seven patients had
good local control of their thoracic disease but developed distant
metastasis after 4-18 months. One patient died of pulmonary
embolism 8 days after resection. Post-mortem examination
showed extensive necrosis in the remaining tumour but no damage
to normal structures such as the heart and the oesophagus.
In all previous studies with PDT its potential has been well
recognized, but the lack of understanding of dosimetry and the
inability to administeradequatelight doses in a shortperiod oftime
has prevented a more general use of PDT. The development of
second generation photosensitizers, with a higher singlet oxygen
yield, have made PDT treatment more attractive, especially for
larger areas. The higher activity ofthephotosensitizers andthe new
types of high-power diode lasers now available enables the treat-
ment period to be considerably shortened. We have been able to
apply this adjuvant photodynamic treatment in 40-60 min. The
shorter halflife or reduced retention in the skin ofsuchphotosensi-
tizers also greatly reduces the skinphotosensitivity forthepatients.
The cumulative light dose (fluence) to the tissues ofthe thoracic
cavity can be measured by isotropic probes in real-time. This is
independent of the optical properties of the tissues in the cavity,
which may vary considerably between patients. These differences
are enhanced by multiple reflections in a closed cavity with walls
ofscattering tissue (Van Staveren et al, 1994). The prescribed light
dose, based on the use of isotropic probes for in situ dosimetry,
will be lower than the same dose specified with the use of flat
detectors, because the flat detectors do not detect all thelight in the
tissue. It is therefore impossible to compare results from different
studies on the basis of incident light dose alone. To overcome this
problem, generally accepted methods of light delivery and
measurement should be developed for specific clinical settings.
The total light dose received by the target tissue should be
described by in situ dosimetry measurements. With the simple illu-
mination technique used in this study, one spherical diffuser occa-
sionally supplemented with a micro-lens illumination, it was
possible to achieve a controlled distribution of the light delivered
to the thoracic cavity. The on-line measurement allows for reposi-
tioning of the diffuser during the treatment, thereby correcting for
asymmetry in the fluence rate distributions and preventing under-
or over-illumination of some areas. Great care must be taken when
illuminating the cavity sequentially with adjoining light fields, as
has been done in several studies (e.g. Ris et al, 1996), as the scat-
tered light contributes a considerable amount to the dose received
on locations that are not directly illuminated. This could lead to
overdosing of some areas, unless this is continuously monitored
during illumination.
In this study we have shown that the combination of PDT and
surgical resection for pleural tumours is feasible and that in situ
light dosimetry greatly improves the reproducibility and controlla-
bility ofthis combined treatment. The operation time increased by
less than 1 h (on an average of5 h surgery alone) in the current set-
up and the duration of the hospital stay was generally no longer
than expected for surgery alone. Larger numbers of patients and
longerfollow-up will be required to determine whether this type of
adjuvant treatment offers a benefit in terms of local control and
survival. The absence oftumour recurrence and survival, observed
in four offive patients so far, is promising. In the patient who died
with recurrence after7 months, tumour cells may have been spread
from the thoracoscopic entrance. We have therefore abandoned the
practice of leaving an indwelling thoracoport for 24 h biopsy
sampling.
Tissue specimens, taken 24 h after treatment, showed extensive
damage to the tumour tissue and only minor damage to striated
muscle of the chest wall after a light dose of only 10 J cm-2 .
Clearly the light dose and/or the drug dose could be escalated or
the time interval between drug administration and illumination
could be reduced in an attempt to achieve better results.
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The improvements in methods of light administration and
dosimetry greatly improve the possibility of safely applying PDT
on larger surfaces. Using this information as a starting point, we
are now planning further dose escalation and phase II studies.
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